Andrew Alasdair Smith, Chief Operating Officer of Medicus Pharma Ltd., filed a Form 4 on November 17, 2026, disclosing the acquisition of 14,534 common shares on November 13, 2026, through a private placement subscription agreement.

Key Highlights

  • Reporting person: Andrew Alasdair Smith, Chief Operating Officer of Medicus Pharma Ltd. (NASDAQ:MDCX)
  • Transaction date: November 13, 2026
  • Shares acquired: 14,534 common shares, no par value, at a purchase price of $1.72 per share
  • Transaction type: Acquisition (Code A) via a private placement subscription agreement
  • Beneficial ownership following transaction: 29,243 common shares held directly
  • Other participants: According to the filing, other investors also participated in the same private placement under separate subscription agreements

Medicus Pharma COO Acquires Shares in November 2026 Private Placement

According to the Form 4 filing submitted to the SEC on November 17, 2026, Andrew Alasdair Smith, the Chief Operating Officer of Medicus Pharma Ltd. (NASDAQ:MDCX), acquired 14,534 common shares, no par value, at a purchase price of $1.72 per share on November 13, 2026. The filing identifies the transaction code as "A," indicating an acquisition of securities.

The filing states that on November 13, 2026, Smith "entered into a subscription agreement with the Issuer, pursuant to which Mr. Smith agreed to purchase 14,534 common shares, no par value, at a purchase price of $1.72 per share in a private placement in which other investors also participated under separate subscription agreements." Following this transaction, the filing reports that Smith directly beneficially owns 29,243 common shares.

The Form 4 was signed by Raza Bokhari as Attorney-in-Fact for Andrew A. Smith and filed on November 17, 2026. No derivative securities transactions were reported in Table II of the filing. The filing was submitted as an individual, single-reporting-person form.

What Was Disclosed

Medicus Pharma Ltd.'s Chief Operating Officer, Andrew Alasdair Smith, disclosed the purchase of 14,534 common shares at $1.72 per share through a private placement on November 13, 2026, bringing his direct beneficial ownership to 29,243 shares, according to the Form 4 filed November 17, 2026.